Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated
variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
May 16, 2000
Jay FlatleyExecutive Chairman of the Board
Francis deSouzaPresident, Chief Executive Officer, Director
Sam SamadChief Financial Officer, Senior Vice President
Marc StapleyExecutive Vice President, Chief Administrative Officer
Garret HamptonExecutive Vice President - Clinical Genomics
Omead OstadanExecutive Vice President - Operations, Products and Strategy
Mostafa RonaghiChief Technology Officer, Senior Vice President
Charles DadswellSenior Vice President, General Counsel, Secretary
Mark Van OeneSenior Vice President, Chief Commercial Officer
Arthur BowmanLead Independent Director
5200 Illumina Way San Diego, CA United States Phone: +1 858 202-4500 Fax: +1 858 202-4766 www.illumina.com
Net income grew by 6.94%, year over year, to (U.S.) $0.87 per share during the most recently completed quarter. This was among the strongest growth seen by any company in this industry.